Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1992 1
1994 4
1996 1
1997 2
1998 1
1999 1
2000 2
2001 3
2002 1
2003 1
2004 1
2005 1
2007 1
2009 2
2011 2
2012 1
2013 1
2014 1
2015 1
2016 5
2017 1
2018 4
2019 5
2020 7
2021 6
2022 4
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

59 results

Results by year

Filters applied: . Clear all
Page 1
Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS.
Miller TM, Cudkowicz ME, Genge A, Shaw PJ, Sobue G, Bucelli RC, Chiò A, Van Damme P, Ludolph AC, Glass JD, Andrews JA, Babu S, Benatar M, McDermott CJ, Cochrane T, Chary S, Chew S, Zhu H, Wu F, Nestorov I, Graham D, Sun P, McNeill M, Fanning L, Ferguson TA, Fradette S; VALOR and OLE Working Group. Miller TM, et al. Among authors: fanning l. N Engl J Med. 2022 Sep 22;387(12):1099-1110. doi: 10.1056/NEJMoa2204705. N Engl J Med. 2022. PMID: 36129998 Free article. Clinical Trial.
Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS.
Miller T, Cudkowicz M, Shaw PJ, Andersen PM, Atassi N, Bucelli RC, Genge A, Glass J, Ladha S, Ludolph AL, Maragakis NJ, McDermott CJ, Pestronk A, Ravits J, Salachas F, Trudell R, Van Damme P, Zinman L, Bennett CF, Lane R, Sandrock A, Runz H, Graham D, Houshyar H, McCampbell A, Nestorov I, Chang I, McNeill M, Fanning L, Fradette S, Ferguson TA. Miller T, et al. Among authors: fanning l. N Engl J Med. 2020 Jul 9;383(2):109-119. doi: 10.1056/NEJMoa2003715. N Engl J Med. 2020. PMID: 32640130 Free article. Clinical Trial.
Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study.
Benatar M, Wuu J, Andersen PM, Bucelli RC, Andrews JA, Otto M, Farahany NA, Harrington EA, Chen W, Mitchell AA, Ferguson T, Chew S, Gedney L, Oakley S, Heo J, Chary S, Fanning L, Graham D, Sun P, Liu Y, Wong J, Fradette S. Benatar M, et al. Among authors: fanning l. Neurotherapeutics. 2022 Jul;19(4):1248-1258. doi: 10.1007/s13311-022-01237-4. Epub 2022 May 18. Neurotherapeutics. 2022. PMID: 35585374 Free PMC article. Clinical Trial.
Author Reply.
Fanning L, Woods E, Hornung CJ, Perrett KP, Tang MLK, Dalziel K. Fanning L, et al. Value Health. 2022 Aug;25(8):1460-1462. doi: 10.1016/j.jval.2022.01.019. Epub 2022 Mar 12. Value Health. 2022. PMID: 35292193 Free article. No abstract available.
Randomized phase I clinical trial of anti-α-synuclein antibody BIIB054.
Brys M, Fanning L, Hung S, Ellenbogen A, Penner N, Yang M, Welch M, Koenig E, David E, Fox T, Makh S, Aldred J, Goodman I, Pepinsky B, Liu Y, Graham D, Weihofen A, Cedarbaum JM. Brys M, et al. Among authors: fanning l. Mov Disord. 2019 Aug;34(8):1154-1163. doi: 10.1002/mds.27738. Epub 2019 Jun 17. Mov Disord. 2019. PMID: 31211448 Free PMC article. Clinical Trial.
Long-term disruption of cytokine signalling networks is evident in patients who required hospitalization for SARS-CoV-2 infection.
Ahearn-Ford S, Lunjani N, McSharry B, MacSharry J, Fanning L, Murphy G, Everard C, Barry A, McGreal A, Al Lawati SM, Lapthorne S, Sherlock C, McKeogh A, Jackson A, Faller E, Horgan M, Sadlier C, O'Mahony L. Ahearn-Ford S, et al. Among authors: fanning l. Allergy. 2021 Sep;76(9):2910-2913. doi: 10.1111/all.14953. Epub 2021 Jun 7. Allergy. 2021. PMID: 34028045 Free PMC article. No abstract available.
59 results